• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Add-on therapy of herbal formulation rich in standardized fenugreek seed extract in type 2 diabetes mellitus patients with insulin therapy: An efficacy and safety study

    2018-10-12 08:35:08AmitKandhareUdayPhadkeAbhayManePrasadThakurdesaiSunilBhaskaran

    Amit Kandhare, Uday Phadke, Abhay Mane, Prasad Thakurdesai, Sunil Bhaskaran

    1Department of Scientific Affairs, Indus Biotech Private Limited, 1, Rahul Residency, Off Salunke Vihar Road, Kondhwa, Pune - 411048, India

    2Ruby Hall Clinic, 40, Sassoon Road, Pune 411001, India

    3Tulip, Opp. Camp Education Society’s High School, Camp, Pune-411001, India

    Keywords:Add-on therapy Dietary supplement Glycaemic control HbA1c Standardized fenugreek seed extract Type 2 diabetes

    ABSTRACT Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract (IND-2) add-on therapy in type 2 diabetes mellitus (T2DM) patients who were on insulin treatment in prospective, single arm, open-label, uncontrolled, multicentre trial. Methods: T2DM patients (n=30) with aged 18-80 years who were stabilized on insulin treatment with fasting blood sugar (FBS) level between 100-140 mg/dL received IND-2 capsules (700 mg, thrice a day) for 16 weeks. The primary endpoints were an assessment of FBS at week 2, 4, 6, 8, 12 and 16. Secondary end-points include post-prandial blood sugar level, glycosylated Hb (HbA1c), reduction in the dose of insulin and number of hypoglycemic attacks, and improvement in lipid profile at various weeks. Safety and adverse events (AEs)were also assessed during the study. Results: Study was completed in twenty T2DM patients,and there was no significant reduction in FBS and post-prandial blood sugar level after addon therapy of IND-2. However, add-on therapy of IND-2 significantly reduced (P<0.01)the HbA1c values, requirements of insulin and hypoglycemic events as compared with baseline. Total cholesterol, high-density lipoproteins-cholesterol, and low-density lipoproteincholesterol levels were significantly increased (P<0.01) after IND-2 add-on therapy. Body weight and safety outcomes did not differ significantly in IND-2 add-on therapy group at week 16. Additionally, add-on therapy of IND-2 did not produce any serious adverse events.Conclusions: The results of present investigation suggest that add-on therapy of IND-2 with insulin in T2DM patients improves glycaemic control through a decrease in levels of HbA1c and number of insulin doses needed per day without an increase in body weight and risk of hypoglycemia. Thus, IND-2 may provide a safe and well-tolerated add-on therapy option for the management of T2DM.

    1. Introduction

    Type 2 diabetes mellitus (T2DM) is a complex, chronic progressive disease which is most common amongst the various forms of diabetes. It is manifested by hyperglycemia, disturbance in the metabolism of carbohydrate, fat, and protein which could be the result from deficiency secretion of insulin or its actions[1].It is a long-term metabolic disorder which is associated with multiple comorbidities as well as microvascular and macrovascular complications such as retinopathy, nephropathy, neuropathy,cardiomyopathy[2,3]. Numerous epidemiological studies have suggested that obesity, insulin resistance, hyperlipidemia, hypertension, and smoking are the risk factors associated with T2DM[4,5]. The prevalence of T2DM is fast-growing worldwide and now become a major public health problem. The projected prevalence of T2DM is predicted to affect more than 350 million people by 2025 worldwide[6,7]. It also produces significant economic burdens, and in a developing country like India, the cost of illness for diabetic care is estimated at USD 336[8].

    Due to a progressive increase in the costs of treatment, the intensive lifestyle modifications have been suggested as a treatment alternative to decrease the risk for diabetes development[9,10]. However, it is difficult to achieve a targeted glycaemic control with lifestyle modification alone. Hence, a strategic escalation of antidiabetic therapy has suggested by the American Diabetes Association and European Association for the Study of Diabetes[1]. Thus, metformin has been recommended by the American Diabetes Association and European Association for the Study of Diabetes as first-line therapy in combination with lifestyle modifications for patients with T2DM[1]. However, metformin may not be able to effectively control glycaemic goals in the patients with higher baseline glycated hemoglobin (HbA1c) levels. Thus, in such patient management of diabetes needs multiple pharmacological treatments[1,11].

    Dipeptidyl-peptidase-4 inhibitors and sulfonylureas are another optional pharmacological therapies now available[5,12,13] that increases insulin secretion by acting on pancreatic β-cells[14].However, these treatment regimens are associated with decreased β-cell function along with concern for weight management. Thus,adequate control of glycemia is difficult over a long period[15].Thiazolidinediones (such as pioglitazone, rosiglitazone) is another class of oral antihyperglycemic agents that act by regulating glucose and lipid metabolism via modulation of peroxisome proliferatoractivated receptor γ[16]. However, clinical evidence showed the association of use of these agents with myocardial events risk and nephrotoxicity[17].

    It has been suggested that the failure in the maintenance of the targeted level of glycated hemoglobin (HbA1c) is a major cause for the worsening nature of T2DM[18,19]. Thus, the advanced therapy of insulin has been recommended for improvement in glycaemic control[1,20,21]. It has been showed that initiation of the insulin therapy in the patients with metformin-alone helps to achieve the glycaemic control with HbA1c reduction[22]. However, additional risk such as weight gained and hypoglycemia need to be considered while management of T2DM using insulin[23]. Furthermore, cost of insulin, unavailability of insulin by the oral route, medication compliance and insulin resistance are the major obstacles in insulin therapy for the management of T2DM. The add-on therapy with insulin may provide sustained glycaemic control along as well as a decrease in the frequency of use of insulin[24,25]. Therefore, interest in add-on therapies to insulin is increasing amongst diabetic patients.Herbal medicine can be considered as an efficacious and safe treatment alternative for the fulfillment of the unmet medical need as an “add-on therapy” along with insulin in the long-term management of T2DM[26-28]. A wide range of phytoconstituents isolated from herbal origin can act by multiple mechanisms including stimulation of insulin production, increase on insulin sensitivity, reduction in HbA1c, modulation of insulin action, reduction of carbohydrate absorption amongst others[28]. The traditional Indian and Chinese medicines have documented an array of such medications for the T2DM treatment with proven clinical safety and efficacy[29].Camellia sinences, Emblica officinalis, Gymnema sylvestre, Linum usitatissimum, Salacia reticulata, Tribulus terrestris, etc. are few amongst them which showed clinical efficacy and safety in the management of T2DM[30-40].

    Trigonella foenum-graecum Linn. (Fabaceae) (fenugreek) has ancient traditional uses in the treatment of diabetes. Fenugreek possesses a broad spectrum of pharmacological and therapeutic properties including anti-hyperlipidemic, antidiabetic, anticancer,anti-arthritic, antioxidant, antimicrobial, antinociceptive and antiinflammatory potential[41-47]. Fenugreek plays a vital role in the prevention of heart, liver, kidney and spleen diseases[48-53].Several investigators have reported the hypocholesterolemic and anti-diabetic potential of defatted fenugreek seed[43,54]. Studies carried out by various researchers have reported the anti-diabetic potential of fenugreek in an array of animal models[41,42,55] as well as in human subjects[43,54]. These effects are related to the presence of constituents such as alkaloid (Trigonelline) and amino acid (2S,3R,4S, 4-hydroxyisoleucine (4-HI))[56-59]. In this view,the herbal formulation (IND-2) has been developed which is rich in standardized fenugreek seed extract. Previously, the researcher also showed the beneficial effect of herbal formulation rich in standardized fenugreek seed extract in the management of T2DM patients inadequately controlled with a sulphonylurea[60]. However,to our knowledge, add-on therapy of herbal formulation rich in standardized fenugreek seed extract (IND-2) for its the efficacy and safety have not been evaluated in a patient with T2DM who were stabilized on insulin treatment. Hence, present investigation aimed to assess the safety and efficacy of IND-2 add-on therapy in T2DM patients on insulin treatment in prospective, single arm, open-label,uncontrolled, multicentre study.

    2. Materials and methods

    2.1. Study design and protocol

    The study was designed as a prospective, open-label, single arm,uncontrolled, multicentre study to assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract(IND-2) (Table 1) 700 mg, thrice a day as add-on therapy in T2DM patients who were stabilized on insulin treatment. All patients received 3 capsules of IND-2 per day, one in the morning (preferably at 7 am), one in the afternoon (preferably at 3 pm), and one at night(preferably at 11 pm). The capsules were administered one hour before of taking the food or two hours after taking the food. The dose of IND-2 was to be adjusted only when the blood sugar level < 80 mg/dL or 20% less than the previous value. Patients who complained about hypoglycemic attacks were discontinued from the study.

    The study comprised a screening and enrolment period namely week (-2) (visits 1) and week 0 i.e. baseline (visit 2), during which patients continued background medication consisting of a stable dose of insulin, and a treatment period, during which patients received 700 mg thrice a day as add-on therapy of IND-2 added to background medication for 16 weeks. Total eight study visits occurred viz., week 2 (visits 3), week 4 (visit 4), week 6 (visit 5), week 8 (visit 6), week 12 (visit 7) and week 16 (visit 8, i.e., treatment end) (Figure 1).

    Table 1 Composition of IND-2.

    Figure 1. Study design.

    2.2. Inclusion and exclusion

    Eligible patients were: (1) male or female subject aged 18-80 years,(2) T2DM (Non-insulin dependent) patients who were stabilized on insulin treatment, (3) fasting blood sugar (FBS) level between 100 mg/dL and 140 mg/dL including both (100 mg/dL and 140 mg/dL),(4) difference between two blood sugar level readings (Visit 1 and Visit 2) should not be more than 30 mg/dL, (5) written informed consent from the subject, (6) stabilized at the same dose of insulin for a minimum period of 8 weeks, (7) no participation in any other clinical studies during last 60 days.

    Exclusion criteria were subjects with conditions such as (1) severe renal insufficiency defined by a creatinine value above 1.5 mg/dL,(2) severe hepatic insufficiency defined by an SGOT (serum glutamic oxaloacetic transaminase) or SGPT (serum glutamic pyruvic transaminase) value equal or higher than the threefold normal values of the respective laboratory safety value, (3) pregnant, willing to get pregnant or nursing women, (4) participation in a clinical trial during the 60 days before the present trial, (5) simultaneous participation in another clinical trial, (6) cardiovascular disorder.

    2.3. Withdrawal criteria

    The participation in a clinical trial by the subjects may be terminated at any time under the following conditions:

    ·At the discretion of the investigator: subjects can be withdrawn on the discretion of the investigator at any time during the trial if the possibility of any impairment of the subjects’ health cannot be excluded.

    ·At the subject’s request: the subject can withdraw himself from the trial without any reason.

    ·If an adverse event (AE) occurs: if a subject is withdrawn due to an AE, this should be followed up until it has resulted in a stabilized medical condition (recovered, recovered with residual damage,death).

    ·Patients who did not get performed their laboratory testing within 7 days from the end of treatment visit

    ·If patients failed to come within 7 days of the scheduled follow-up visit

    ·If patients become pregnant during the study

    ·If the major protocol violation occurred by the patients: like missing two consecutive visits, not taking medication for 1 week, etc.

    2.4. Compliance with ethics

    All patients provided written and informed consent. The study protocol was approved by the institutional review board of each center (The protocol No. IBHM02/2002). The study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization Guideline for Good Clinical Practice guidelines as defined by the International Conference on Harmonization.

    2.5. Compliance with treatment

    Patients were encouraged not to skip scheduled medication intake or reduce dosages on their own. Lapses observed during visits were documented on the appropriate page of the Case Report Form.Investigators evaluated treatment compliance by measuring unused medication in the subject medication box. If more than 20% of the total prescribed medication was not consumed by the patient during every 2 weeks, the patient was termed as noncompliant and was excluded from the trial.

    2.6. Study endpoints

    The effect of IND-2 (700 mg, thrice a day) on FBS compared with baseline (week 0) was the primary efficacy endpoint. Whereas, the effects of IND-2 on post-prandial blood sugar level (PPBS) and glycosylated Hb (HbA1c), to check the feasibility of reduction in the dose of insulin and number of hypoglycemic attacks after addition of IND-2 and to assess improvement in lipid profile [i.e., triglycerides,high-density lipoproteins-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), total cholesterol (TC), and LDL-C to HDL-C ratio] as compared with the baseline were the secondary efficacy endpoints. Assessment of FBS, PPBS, HbA1c, insulin dose and hypoglycemic attacks were done on all visits (Week 0, 2, 4, 6, 8,12 and 16). The lipid profile was assessed on alternate visits (Week 0, 8 and 16).

    2.7. Safety parameters

    The following safety parameters were investigated to assess the safety of IND-2:

    · The clinical safely was evaluated on all visits by vital signs, ECG recordings, and any AEs which may be spontaneously reported and observed directly.

    · The following vital signs were considered for a measure of clinical safety variable:

    ·The temperature of the body ( ° F)

    ·Respiratory rate (breath/minute)

    ·Systolic blood pressure (mmHg)

    ·Diastolic blood pressure (mmHg)

    ·Heart rate (beats/minute)

    The laboratory safety was evaluated by determining the following parameters at the initiation of treatment (week 0), and after 8 and 16 weeks: Haemoglobin (Hb), white blood cell (WBC): total and differential count, red blood cell (RBC) count, platelet count,mean corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC), erythrocyte sedimentation rate (ESR), total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase(AST), alanine aminotransferase(ALT), lactic dehydrogenase(LDH), serum proteins, urinalysis, blood urea nitrogen (BUN) and creatinine.

    2.8. Blood sampling and measurements

    Blood samples were collected after fasting condition of at least 10 h. Then samples of blood were processed and analyzed in one central laboratory. Samples were handled according to laboratory routines, and the laboratory variables were analyzed according to routine assay techniques at the laboratory.

    2.9. Statistical analysis

    A total of 30 participants were recruited with an assumption of a 20 percent dropout rate. Being a pilot study, no statistical method was applied to decide the sample size. Results are represented as mean± standard deviation (SD). Mean values of various diabetic markers(FBS and PPBS levels, number of hypoglycemic attacks since the last visit, amount of insulin required) and HbA1c at each visit were compared with baseline. The secondary efficacy parameters, i.e.,various lipid markers (TC, LDL-C, HDL-C, triglycerides, the ratio of LDL-C and HDL-C), AEs (haematology and biochemistry) and vital parameters at V6 as well as at V8 were compared with baseline and analyzed using a paired t-test. The P<0.05 was considered statistically significant. The SPSS version 16.0 software used for statistical analysis.

    3. Results

    3.1. Patient recruitment, demographics and baseline characteristics

    Total 60 subjects were screened, and 30 (male = 16 and female 14) were recruited in the trial. Ten subjects were withdrawn from the trial at various stages. The lost of follow-up [4/10 (40%)], and AE [4/10 (40%)] were the most common reasons for treatment discontinuation. Two subjects discontinued due to lack of compliance and inclusion violation. Thus, 20 subjects were considered for the study and received treatment with IND-2 add-on therapy. Figure 2 depicted the patient recruitment and selection process.

    The demographics and baseline characteristics of the subjects were represented in Table 2. At the baseline of the study, mean age was 52 years, HbA1c was 6.19%, BMI was 27.31 kg/m2, FBS levels was 121.71 mg/dL, and PPBS levels was 193.560 mg/dL.

    3.2. Treatment compliance

    After each visit, the unused capsules were counted from which the treatment compliance was determined on a study population of 20. If more than 20% of the total prescribed medication was not consumed by the patient during every 2 weeks, the patient was termed as noncompliant and was excluded from the trial. The mean treatment compliance was > 98%, which was deemed acceptable.

    Figure 2. Patient disposition.

    Table 2 Demographic data (n = 20).

    3.3. Effects of IND-2 add-on therapy on glucose regulation

    There was no statistically significant reduction in FBS and PPBS level at week 2, 4, 6, 8, 12 and 16 after add-on therapy of IND-2 when compared with baseline (week 0) (Figure 3). However, addon therapy of IND-2 with insulin showed a significant decrease(P<0.01) in HbA1c at week 8 compared with the baseline (Figure 4A).Additionally, requirements of insulin (in terms of units consumed per day) at week 2, 6, 8, 12 and 16 were also significantly less (P<0.001,P<0.01, P<0.01, P<0.01 and P<0.01, respectively) after add-on therapy of IND-2 as compared with from baseline (Figure 4B). Furthermore,reductions in hypoglycemic events after add-on therapy of IND-2 at week 2, 6 and 12 were also significantly reduced (P<0.01, P<0.01and P<0.05, respectively) as compared with baseline (Figure 4C).

    Figure 3. Effect of add-on therapy of IND-2 on FBS and PPBS over 16 weeks.Values are shown as the mean ± standard deviation. Data were analyzed by paired “t” test.

    Figure 4. Effect of add-on therapy of IND-2 on the HbA1c level (A), insulin dose (B) and hypoglycemic events (C) over 16 weeks.

    3.4. Effects of IND-2 add-on therapy on lipid profile

    LDL and TC showed a slight but significant increase (P<0.01 and P<0.05) at week 8 in the IND-2 add-on treatment group as compared with the baseline. At 16 weeks of treatment, LDL, HDL,and TC were also significantly increased (P<0.01) as compared with the baseline. However, triglyceride levels and LDL: HDL ratio did not differ significantly at week 8 and 16 when compared with the baseline (Table 3).

    Table 3 Effect of add-on therapy of IND-2 on efficacy variables of lipid profile.

    3.5. Effects of IND-2 on safety outcomes

    At week 16, there was no significant difference in body weight,plasma AST, ALT, protein, and creatinine in add-on therapy with IND-2 as compared with baseline (Table 4). However, treatment with IND-2 showed significantly decreased (P<0.05) in ALP,bilirubin, and significantly increased (P<0.05) in a BUN at week 8 as compared with the baseline but these differences did not continue till week 16 and remain non-significant as compared with the baseline(Table 4).

    Table 4 Effect of add-on therapy of IND-2 on safety parameters.

    The levels of Hb, hematocrit, MCHC, RBC, WBC, eosinophils,neutrophils, lymphocytes, and monocytes did not differ significantly in IND-2 add-on therapy at week 8 and week 16 as compared with the baseline. However, add-on therapy of IND-2 for 8 weeks resulted in a significantly increase (P<0.01) in MCV and platelets levels when compared with baseline, but these changes were discontinued till week 16 and remain non-significant when compared with baseline. Similarly, the respiratory rate was decreased significantly(P<0.05) at week 8 and remained non-significant at week 16 in IND-2 add-on therapy group as compared with the baseline (Table 4).

    3.6. AEs

    Overall AEs and the most common AEs are summarized in Table 5 and Table 6. Add-on therapy of IND-2 did not produce any serious AEs during the clinical study. Total 99 AEs were documented in the study out of which 5 adverse events were graded as severe which includes a cough (2), dyspnoea (1), diarrhea (1), and gastritis (1).Seventeen events were considered as ‘related’ to the test drug, and 4 subjects were discontinued from the trial due to adverse events.

    Table 5 Summary of adverse events experienced by a number of patients at least once.

    Taken individually, absolute frequency of adverse events such as increase in ESR, gastritis/epigastric pain and diarrhea were the first three most commonly observed adverse events. In terms of patients experiencing the adverse events, the same adverse events were most commonly observed. Mean values of some laboratory tests were altered after 8 weeks and returned to normal after 16 weeks. There were no deaths, or serious medical event reported in during this clinical study.

    Table 6 Absolute frequency of adverse events.

    4. Discussion

    T2DM is a chronic, complex heterogeneous condition resulted from impairment of insulin secretion from β cells of the pancreas,insulin action, or insulin resistance in the peripheral tissues. In the last few decades, the prevalence of T2DM increases significantly which makes it one of the most critical growing health issues worldwide. Therefore, the guidance of the American Association of Clinical Endocrinologists recommended the various treatment regimen including dipeptidyl peptidase-4 inhibitors (such as sitagliptin), thiazolidinediones, sulfonylureas, and insulin[61,62].However, these agents are also associated with substantially clinical side effects including a risk of hypoglycemia, increased body weight, lactic acidosis, the risk of myocardial events, etc[1]. Hence,many investigators have employed various add-on therapies from the natural origin for the treatment of T2DM[4,63]. In the present investigation, we have also assessed the safety and efficacy of IND-2 add-on therapy in T2DM patients who were on insulin treatment.The outcomes of the present investigation showed that addition of IND-2 (700 mg, thrice a daily) with insulin treatment for 16 weeks significantly improved the amount of insulin required per day along with significant decrease in of the numbers of hypoglycemic attacks without any serious adverse events.

    Numerous clinical evidence suggests that control over FBS and PPBS level are essential outcomes in the management of T2DM and reflected as the gold standard for overall glycaemic control[64,65]. However, FBS level determination over time course trend failed to provide the detailed information of diabetes status and is also non-satisfactory[66]. Hence, according to the American Diabetes Association, glycated hemoglobin (HbA1c, with a cutpoint ≥6.5%) has been recommended over FBS (≥7.0 mmol/L) for diabetes detection[20]. Furthermore, HbA1c provides an insight about the individual average levels of blood glucose over the last two to three months. Thus, HbA1c is considered as a reliable indicator of chronic glycemia and reflected the risk of various chronic diabetes complications such as retinopathy, neuropathy, nephropathy, etc.Hence, currently, HbA1c is widely used as an essential test for chronic management of diabetes. In the present investigation, we have also determined the effect of add-on therapy of IND-2 on HbA1c and result show that it significantly decreased HbA1c levels over 8 weeks.Fenugreek (Trigonella foenum-graecum), E. officinalis, G. sylvestre, S.reticulata, and C. sinensis were reported to reduce the HbA1clevel in clinical and preclinical studies[30-36,67]. Additionally, the presence of 4-HI in standardized fenugreek seed extract may be responsible for the reduction in HbA1c level in T2DM patients and the findings of the previous investigator also support this notion[56-59].

    The management of T2DM many time needs the combination of oral antidiabetic therapies including sulfonylureas, DDP-4 inhibitors. However, these therapies are substantially limited by its side effects[1]. Hence, many T2DM patients eventually moved to insulin therapy for maintaining better glycaemic control. Although insulin is the most effective treatment available for the management of blood glucose levels, it is still also associated with side effects such as weight gain and risk of hypoglycaemia[1,23]. Therefore, in such patients, there is a need for add-on therapy with more viable and safe option. In the present investigation, we have implicated IND-2 as an add-on therapy along with insulin for the management of T2DM. The finding showed that IND-2 with insulin decreased(27% reduction) the number of insulin dose needed per day as compared with baseline. The observed beneficial effects of IND-2 on top of insulin are anticipated from its complementary mechanism of action. This action of IND-2 may depend on the amount of glucose present which caused the secretion of insulin. This mechanism of action of IND-2 is further supported by the decrease in the number of hypoglycemic events over 16 weeks. Whereas, sulfonylurea has a limitation where it caused continuous stimulation of insulin secretion, even with decreasing level of glucose which results in hypoglycemia[1]. Thus, clinically IND-2 can be considered as a potential add-on therapeutic agent with insulin for T2DM management, with a decrease in hypoglycemia risk and a decrease in the number of insulin doses needed per day.

    Further, we have also investigated the effect of IND-2 on lipids profile which showed that a moderate but significant increase in total, HDL and LDL cholesterol over 16 weeks. It has been well documented that elevated level of cholesterol associated with risk for CHD (coronary heart disease) and atherosclerosis[68]. However,a recent clinical study also reported that vildagliptin add-on therapy with insulin improves control on glycemia with an increase in the risk of hyperlipidemia[69]. In the present investigation, documented increase in lipid profile might be a secondary effect resulting from decreased HbA1c levels.

    According to the ADA/EASD guidelines, the treatment approach for T2DM therapy should be based on patient-centric which should consider various aspects including the need for treatment, preference of patient and values[1]. Although ADA/EASD recommends insulin as effective treatment for the management of T2DM, weight gain is a common side effect associated with it. Thus, weight control during the treatment of diabetes is an important consideration for the T2DM management therapy. In the present study, body weight in add-on therapy of IND-2 with insulin did not differ significantly despite significant improvement in HbA1c which can be considered an advantage of IND-2 along with insulin treatment.

    Traditional medicines are considered to be relatively safe option with low side-effects, but their efficacy is found relatively low as compared with Western medicines. Hence, many times the high dose was usually needed to attend the optimal therapeutic efficacy. Thus,their toxicity cannot be neglected in the view of their therapeutic applications[70]. The common adverse event associated with herbal supplementation includes complications related to gastrointestinal tracts such as nausea, vomiting, diarrhea, and constipation[71].Also, herb-drug interaction related to pharmacokinetics and pharmacodynamics properties needs to be considered during their administration. In the present investigation, add-on therapy of IND-2 with insulin was well tolerated. There was no any serious AEs were reported during the trial. Among the reported AEs, the majority of the events were mild and not related to the IND-2 add-on therapy.However, discontinuation of 4 subjects from the trial due to adverse events is a significant finding. The previous investigator also reported similar kind of cause which lead to treatment discontinuation[72,73].Increased ESR is reported in a maximum number of patients and tops the list of the number of absolute adverse events. Though, the rise in ESR was reported as not related to drugs, there is a need for further studies with a large number of patient population to confirm the effect of IND-2 on ESR. All the events, which were related to the drug were gastrointestinal tract events. Six significant abnormalities in laboratory parameters were observed which were present during week 8 and not continued till week 16.

    Recent year various researchers have investigated the effect of polyherbal formulation on HbA1c levels[74,75]. Administration of polyherbal formulation that contains Gymnema sylvestre extract in T2DM for 3 months showed significant improvement in HbA1c levels and antioxidant enzyme activities[74]. Furthermore, a polyherbal formulation containing standardized extracts of Trigonella foenum-graecum and Emblica officinalis also showed a decrease in HbA1c, FBS and PPBS in the T2DM patient with uncontrolled blood sugar despite a sulfonylurea and metformin stable dose[65].These studies suggested that Trigonella foenum-graecum, Gymnema sylvestre, and Emblica officinalis were most widely implemented herbs for preparation of polyherbal formulations in the management of diabetes. Additionally, safety and efficacy of Trigonella foenumgraecum as an anti-diabetic medication have also been well established clinically[76,77]. Thus, results of current investigation along with findings of earlier researchers both substantially provide the potential of this polyherbal formulation (IND-2) as a safe and well-tolerated add-on treatment option for the T2DM management in the patients with insulin treatment.

    The present investigation has certain limitations. The primary limitation of this study is a single-arm study without placebocontrol. Hence, study with placebo-control will be required to assess comparative efficacy of IND-2 in T2DM subjects. Secondly, the sample size of the present investigation is relatively too small, and the study duration is also too short which provides only short-term effects. Hence, analysis of long-term effect with larger sample size remains to be evaluated. Lastly, in this study, we have not evaluated the parameters which give an insight to the possible mechanism of action of IND-2 such as serum insulin level, molecular markers in blood, level of antioxidants in blood, etc.

    The findings of present investigation suggest that add-on therapy of IND-2 (herbal formulation rich in standardized fenugreek seed extract) with insulin in T2DM patients improved glycaemic control through a decrease in levels of glycated hemoglobin and number of insulin doses needed per day without a change in blood sugar, body weight and risk of hypoglycemia. Thus, IND-2 may provide a safe and well-tolerated add-on therapy option for the management of T2DM.

    Conflict of interest statement

    Amit Kandhare and Prasad Thakurdesai are the full-time employees of Indus Biotech Pvt. Ltd., Pune.

    Acknowledgments

    The authors gratefully acknowledge the support of all the investigators and medical staff at the participating centers. The authors would also like to acknowledge Hanul Medizin Pvt. Ltd.,Pune, India for clinical research services. This work was funded by Indus Biotech Pvt. Ltd., Pune.

    欧美zozozo另类| 久久精品夜夜夜夜夜久久蜜豆| 国产视频内射| 亚洲国产精品成人综合色| 高清毛片免费观看视频网站| 51国产日韩欧美| 欧美国产日韩亚洲一区| 男人狂女人下面高潮的视频| 久久久久久久亚洲中文字幕 | 亚洲乱码一区二区免费版| 日韩精品中文字幕看吧| 亚洲成av人片在线播放无| 日韩国内少妇激情av| 国产午夜福利久久久久久| 男女下面进入的视频免费午夜| 亚洲av.av天堂| 麻豆国产97在线/欧美| 性色avwww在线观看| 美女cb高潮喷水在线观看| 久久九九热精品免费| 国产精品久久久久久久久免 | 亚洲自拍偷在线| 欧美黄色片欧美黄色片| 丝袜美腿在线中文| 亚州av有码| 丰满乱子伦码专区| 日韩高清综合在线| 蜜桃亚洲精品一区二区三区| 国产精品野战在线观看| 国内精品一区二区在线观看| 日本成人三级电影网站| 亚洲国产精品999在线| 色精品久久人妻99蜜桃| 日本免费a在线| 亚洲成av人片免费观看| 99热这里只有是精品在线观看 | 亚洲av美国av| av视频在线观看入口| 国产黄色小视频在线观看| 给我免费播放毛片高清在线观看| 久久草成人影院| 国产成人欧美在线观看| 老司机午夜福利在线观看视频| www.熟女人妻精品国产| 免费人成在线观看视频色| 亚洲一区二区三区不卡视频| av福利片在线观看| 嫩草影视91久久| 草草在线视频免费看| 国产成人福利小说| 成人午夜高清在线视频| 国产精品嫩草影院av在线观看 | 亚洲av免费高清在线观看| 99在线视频只有这里精品首页| 最后的刺客免费高清国语| 国产精品爽爽va在线观看网站| 露出奶头的视频| 18禁黄网站禁片午夜丰满| 丁香六月欧美| 日本与韩国留学比较| 深爱激情五月婷婷| 两人在一起打扑克的视频| 国产熟女xx| av在线观看视频网站免费| 一个人免费在线观看的高清视频| 女人被狂操c到高潮| 国产午夜精品论理片| 亚洲成人精品中文字幕电影| 久久亚洲真实| 午夜精品一区二区三区免费看| 亚洲精品在线美女| 亚洲精品粉嫩美女一区| 欧美黄色淫秽网站| h日本视频在线播放| 久久亚洲精品不卡| 亚洲成av人片免费观看| 日日摸夜夜添夜夜添小说| 久久精品人妻少妇| 亚洲av第一区精品v没综合| 亚洲第一欧美日韩一区二区三区| 黄色日韩在线| 久久人人爽人人爽人人片va | 又紧又爽又黄一区二区| 十八禁网站免费在线| 精品欧美国产一区二区三| 日韩大尺度精品在线看网址| 国产av在哪里看| 亚洲最大成人av| 色视频www国产| 一个人看视频在线观看www免费| 91av网一区二区| 69av精品久久久久久| 亚洲男人的天堂狠狠| 国产精品98久久久久久宅男小说| 精品午夜福利在线看| av女优亚洲男人天堂| 日日摸夜夜添夜夜添小说| 国产精品影院久久| 欧美黑人巨大hd| 一卡2卡三卡四卡精品乱码亚洲| 99久国产av精品| 国产午夜精品久久久久久一区二区三区 | 91九色精品人成在线观看| 国产精品98久久久久久宅男小说| 人人妻,人人澡人人爽秒播| 他把我摸到了高潮在线观看| 国产一区二区三区在线臀色熟女| 午夜老司机福利剧场| 男人狂女人下面高潮的视频| 中文字幕久久专区| 国产精品1区2区在线观看.| 一a级毛片在线观看| 18美女黄网站色大片免费观看| 真实男女啪啪啪动态图| 日韩欧美 国产精品| 中文字幕熟女人妻在线| 欧美国产日韩亚洲一区| 91字幕亚洲| 一级毛片久久久久久久久女| 亚洲天堂国产精品一区在线| 日本五十路高清| 69人妻影院| 亚洲精品乱码久久久v下载方式| 国产视频一区二区在线看| 亚洲国产欧洲综合997久久,| 性欧美人与动物交配| 又黄又爽又免费观看的视频| 欧美精品国产亚洲| 国产精品亚洲av一区麻豆| 成人国产综合亚洲| 九色成人免费人妻av| 老司机午夜十八禁免费视频| 黄色日韩在线| 久久久久久大精品| 99久久成人亚洲精品观看| 亚洲中文字幕一区二区三区有码在线看| 久久精品综合一区二区三区| 蜜桃久久精品国产亚洲av| 亚洲 欧美 日韩 在线 免费| 免费大片18禁| 日韩大尺度精品在线看网址| 中文字幕人成人乱码亚洲影| 一级作爱视频免费观看| 日韩精品中文字幕看吧| 床上黄色一级片| 麻豆av噜噜一区二区三区| 亚洲色图av天堂| 欧美黑人欧美精品刺激| 99久国产av精品| 99视频精品全部免费 在线| 久久精品影院6| 在线看三级毛片| 国产毛片a区久久久久| 丰满人妻一区二区三区视频av| 熟女人妻精品中文字幕| 变态另类成人亚洲欧美熟女| 国产高清三级在线| 两个人的视频大全免费| 亚洲av一区综合| 久久伊人香网站| 免费在线观看影片大全网站| 亚洲av一区综合| 中文字幕人妻熟人妻熟丝袜美| 日本免费一区二区三区高清不卡| 露出奶头的视频| 99久国产av精品| 亚洲 欧美 日韩 在线 免费| 欧美性感艳星| 淫妇啪啪啪对白视频| 人人妻人人澡欧美一区二区| 免费搜索国产男女视频| 真人做人爱边吃奶动态| 婷婷色综合大香蕉| 久久久国产成人免费| 国产伦在线观看视频一区| 色综合亚洲欧美另类图片| 成年人黄色毛片网站| 国产在线男女| 日韩欧美国产一区二区入口| 男女之事视频高清在线观看| 国产精品一区二区免费欧美| 精品一区二区三区视频在线观看免费| 极品教师在线免费播放| 精品人妻一区二区三区麻豆 | 午夜视频国产福利| 国产私拍福利视频在线观看| 极品教师在线视频| 日本免费一区二区三区高清不卡| 国产精品久久久久久人妻精品电影| 一本精品99久久精品77| 美女大奶头视频| 久久久久九九精品影院| 搡老熟女国产l中国老女人| 久久亚洲精品不卡| 夜夜夜夜夜久久久久| 国产白丝娇喘喷水9色精品| 欧美精品国产亚洲| 简卡轻食公司| 精品久久久久久久久久免费视频| 国产精品综合久久久久久久免费| 我要搜黄色片| 久久伊人香网站| 日本黄大片高清| 有码 亚洲区| 毛片女人毛片| 中文在线观看免费www的网站| 麻豆成人av在线观看| 九九久久精品国产亚洲av麻豆| 国产精品久久久久久人妻精品电影| 成熟少妇高潮喷水视频| 成年版毛片免费区| 国内揄拍国产精品人妻在线| 亚洲国产精品成人综合色| 亚洲人成网站在线播| 免费无遮挡裸体视频| avwww免费| 18美女黄网站色大片免费观看| 一本精品99久久精品77| 色哟哟哟哟哟哟| 亚洲精品粉嫩美女一区| 熟女人妻精品中文字幕| 日本黄色视频三级网站网址| 亚洲av第一区精品v没综合| 人妻丰满熟妇av一区二区三区| 18禁黄网站禁片免费观看直播| 麻豆国产av国片精品| 黄色配什么色好看| 欧美性猛交╳xxx乱大交人| 一本精品99久久精品77| 久久精品夜夜夜夜夜久久蜜豆| 国产精品美女特级片免费视频播放器| 精品国产亚洲在线| 欧美xxxx黑人xx丫x性爽| 9191精品国产免费久久| 九色成人免费人妻av| 亚洲精品乱码久久久v下载方式| 日韩欧美国产一区二区入口| 国产亚洲av嫩草精品影院| 欧美+日韩+精品| 亚洲18禁久久av| 欧美极品一区二区三区四区| 精品不卡国产一区二区三区| av欧美777| 国产精品三级大全| 性色avwww在线观看| 级片在线观看| 动漫黄色视频在线观看| 国产国拍精品亚洲av在线观看| 最近在线观看免费完整版| 日韩大尺度精品在线看网址| 成人av一区二区三区在线看| 国产亚洲欧美在线一区二区| 午夜激情欧美在线| 在线国产一区二区在线| 99国产极品粉嫩在线观看| 亚洲七黄色美女视频| 亚洲国产精品久久男人天堂| 波野结衣二区三区在线| 在线观看美女被高潮喷水网站 | 婷婷六月久久综合丁香| 男人狂女人下面高潮的视频| 大型黄色视频在线免费观看| 好男人在线观看高清免费视频| 国产乱人伦免费视频| 90打野战视频偷拍视频| 国产激情偷乱视频一区二区| 国产成年人精品一区二区| 中文字幕免费在线视频6| 又粗又爽又猛毛片免费看| 日韩高清综合在线| 欧美最新免费一区二区三区 | 真人做人爱边吃奶动态| 变态另类丝袜制服| 久久久久久久亚洲中文字幕 | 成人一区二区视频在线观看| 日韩欧美三级三区| 99久久成人亚洲精品观看| 精品人妻视频免费看| 久久久国产成人免费| 在线a可以看的网站| 亚洲av一区综合| 麻豆一二三区av精品| 99热只有精品国产| av黄色大香蕉| 亚洲综合色惰| 色尼玛亚洲综合影院| 久久国产乱子伦精品免费另类| 国产真实乱freesex| 中文亚洲av片在线观看爽| 亚洲欧美日韩卡通动漫| 日韩国内少妇激情av| 露出奶头的视频| 中文字幕久久专区| 亚洲av.av天堂| 欧美另类亚洲清纯唯美| 美女免费视频网站| 性欧美人与动物交配| 日韩精品青青久久久久久| 久久九九热精品免费| 变态另类成人亚洲欧美熟女| 精品久久久久久久末码| 亚洲专区国产一区二区| 亚洲五月天丁香| 伊人久久精品亚洲午夜| 最近视频中文字幕2019在线8| 欧美潮喷喷水| 精品久久国产蜜桃| 国产精品电影一区二区三区| 亚洲内射少妇av| 国产在线精品亚洲第一网站| 久久中文看片网| 日韩欧美在线二视频| 久久精品夜夜夜夜夜久久蜜豆| 两人在一起打扑克的视频| 久久精品人妻少妇| 午夜激情福利司机影院| 久久久久亚洲av毛片大全| 真人一进一出gif抽搐免费| 麻豆成人av在线观看| 国产精品久久久久久人妻精品电影| 国产精品99久久久久久久久| 午夜亚洲福利在线播放| 欧美乱色亚洲激情| 观看美女的网站| netflix在线观看网站| 精品久久国产蜜桃| 午夜视频国产福利| 噜噜噜噜噜久久久久久91| a级一级毛片免费在线观看| 十八禁网站免费在线| 男女那种视频在线观看| 亚洲av美国av| 免费观看精品视频网站| 国产一区二区在线av高清观看| 夜夜躁狠狠躁天天躁| 黄片小视频在线播放| www.熟女人妻精品国产| 国产精品一及| 成人美女网站在线观看视频| 久久人人爽人人爽人人片va | 久久婷婷人人爽人人干人人爱| 午夜福利成人在线免费观看| avwww免费| 色综合欧美亚洲国产小说| 日本与韩国留学比较| 日本撒尿小便嘘嘘汇集6| 午夜福利在线在线| 国产69精品久久久久777片| 久久久久亚洲av毛片大全| 热99re8久久精品国产| 老熟妇仑乱视频hdxx| 别揉我奶头~嗯~啊~动态视频| 不卡一级毛片| 国产精品美女特级片免费视频播放器| 此物有八面人人有两片| xxxwww97欧美| 精品人妻视频免费看| 性欧美人与动物交配| 村上凉子中文字幕在线| 特大巨黑吊av在线直播| 国产高清激情床上av| 日韩欧美在线二视频| 搡女人真爽免费视频火全软件 | 18美女黄网站色大片免费观看| 网址你懂的国产日韩在线| 99久久无色码亚洲精品果冻| 在线观看66精品国产| 欧美成人一区二区免费高清观看| 亚洲中文字幕日韩| 给我免费播放毛片高清在线观看| 日韩欧美 国产精品| 日韩有码中文字幕| 人人妻,人人澡人人爽秒播| 一级黄片播放器| 日本五十路高清| 亚洲成a人片在线一区二区| 此物有八面人人有两片| 美女高潮的动态| 亚洲真实伦在线观看| 99久久精品国产亚洲精品| 久久欧美精品欧美久久欧美| 最新在线观看一区二区三区| 亚洲精品成人久久久久久| 91麻豆av在线| 久久婷婷人人爽人人干人人爱| 丰满人妻熟妇乱又伦精品不卡| 午夜a级毛片| 精品久久久久久成人av| 亚洲片人在线观看| 亚洲天堂国产精品一区在线| 免费高清视频大片| 丁香六月欧美| 超碰av人人做人人爽久久| 脱女人内裤的视频| 国产精品自产拍在线观看55亚洲| 国产精品乱码一区二三区的特点| 亚洲av熟女| 亚洲经典国产精华液单 | 欧美+亚洲+日韩+国产| 亚洲欧美激情综合另类| 婷婷色综合大香蕉| 级片在线观看| 亚洲熟妇熟女久久| 18+在线观看网站| 免费看美女性在线毛片视频| 欧美不卡视频在线免费观看| 桃红色精品国产亚洲av| 午夜福利高清视频| 美女高潮的动态| 欧美在线黄色| 久久精品国产亚洲av天美| 亚洲激情在线av| 亚洲在线自拍视频| 淫秽高清视频在线观看| 少妇熟女aⅴ在线视频| 毛片一级片免费看久久久久 | 91午夜精品亚洲一区二区三区 | 亚洲va日本ⅴa欧美va伊人久久| 女人十人毛片免费观看3o分钟| 国产乱人伦免费视频| 亚洲精品久久国产高清桃花| 国语自产精品视频在线第100页| 一个人免费在线观看的高清视频| 国产色爽女视频免费观看| ponron亚洲| 欧美性猛交╳xxx乱大交人| 国产av麻豆久久久久久久| 色综合站精品国产| 亚洲va日本ⅴa欧美va伊人久久| 免费搜索国产男女视频| 永久网站在线| 很黄的视频免费| 亚洲欧美日韩无卡精品| 国产成人啪精品午夜网站| 免费av毛片视频| 怎么达到女性高潮| 舔av片在线| 国内精品一区二区在线观看| 亚洲欧美清纯卡通| 久久热精品热| 久久草成人影院| 精品一区二区免费观看| 免费在线观看日本一区| 乱人视频在线观看| 国语自产精品视频在线第100页| 亚洲五月婷婷丁香| 亚洲精品亚洲一区二区| 精品日产1卡2卡| 99久久精品热视频| 可以在线观看毛片的网站| 亚洲狠狠婷婷综合久久图片| 久久草成人影院| 性欧美人与动物交配| 身体一侧抽搐| 夜夜爽天天搞| 国产精品亚洲美女久久久| 国产成年人精品一区二区| 亚洲avbb在线观看| 国产野战对白在线观看| 国产精品嫩草影院av在线观看 | 成人鲁丝片一二三区免费| ponron亚洲| 美女cb高潮喷水在线观看| h日本视频在线播放| 69av精品久久久久久| 内射极品少妇av片p| 听说在线观看完整版免费高清| 亚洲三级黄色毛片| 亚洲,欧美精品.| 午夜久久久久精精品| 久久精品夜夜夜夜夜久久蜜豆| 婷婷丁香在线五月| 精品久久久久久,| 亚洲欧美激情综合另类| 91午夜精品亚洲一区二区三区 | 精品熟女少妇八av免费久了| 每晚都被弄得嗷嗷叫到高潮| 日本一二三区视频观看| 12—13女人毛片做爰片一| 成年免费大片在线观看| 精品一区二区免费观看| 日日摸夜夜添夜夜添小说| 性色av乱码一区二区三区2| 在线观看66精品国产| 别揉我奶头~嗯~啊~动态视频| 午夜影院日韩av| 国产成人啪精品午夜网站| 欧美黑人欧美精品刺激| 国产熟女xx| 中国美女看黄片| 美女高潮喷水抽搐中文字幕| 成人欧美大片| 成人午夜高清在线视频| 国产免费一级a男人的天堂| 欧美3d第一页| 久久久久久久久大av| 国产在线男女| 色播亚洲综合网| 亚洲第一区二区三区不卡| 99久久精品国产亚洲精品| 国产主播在线观看一区二区| 丁香六月欧美| 99国产精品一区二区蜜桃av| 免费在线观看影片大全网站| 免费看日本二区| 在线免费观看的www视频| 亚洲成av人片在线播放无| 欧美黑人巨大hd| 国产爱豆传媒在线观看| 欧美日韩亚洲国产一区二区在线观看| 亚洲激情在线av| 少妇的逼水好多| 久久亚洲真实| 国产爱豆传媒在线观看| 免费黄网站久久成人精品 | 成人永久免费在线观看视频| www.www免费av| 人人妻,人人澡人人爽秒播| 日本三级黄在线观看| 久久精品综合一区二区三区| 免费无遮挡裸体视频| 成人性生交大片免费视频hd| 欧美bdsm另类| 天堂av国产一区二区熟女人妻| 欧美zozozo另类| 91久久精品电影网| 亚洲av电影不卡..在线观看| 国产精品,欧美在线| 赤兔流量卡办理| 欧美黑人巨大hd| 好男人电影高清在线观看| 亚洲久久久久久中文字幕| 国产一区二区激情短视频| 欧美绝顶高潮抽搐喷水| 亚洲欧美日韩高清专用| 日韩成人在线观看一区二区三区| 成人美女网站在线观看视频| 免费观看人在逋| 欧美日韩黄片免| 亚洲成a人片在线一区二区| 免费av毛片视频| 亚洲午夜理论影院| 性色avwww在线观看| 国产av在哪里看| 国产大屁股一区二区在线视频| 国产精品爽爽va在线观看网站| 在线a可以看的网站| 久久久久性生活片| 久久久久久久久大av| 99久久99久久久精品蜜桃| 18禁裸乳无遮挡免费网站照片| 国产精品影院久久| 国产色爽女视频免费观看| 我要搜黄色片| 国产免费一级a男人的天堂| 欧美成人免费av一区二区三区| 国产黄a三级三级三级人| 国产精品乱码一区二三区的特点| 国产真实乱freesex| 最新中文字幕久久久久| 成人精品一区二区免费| 中亚洲国语对白在线视频| 99国产极品粉嫩在线观看| 又爽又黄a免费视频| 超碰av人人做人人爽久久| 亚洲电影在线观看av| 亚洲成人久久爱视频| 午夜影院日韩av| 亚洲av电影不卡..在线观看| 婷婷色综合大香蕉| 日本在线视频免费播放| 日本精品一区二区三区蜜桃| 窝窝影院91人妻| 精品久久国产蜜桃| 国产精品电影一区二区三区| av在线天堂中文字幕| 日日摸夜夜添夜夜添av毛片 | 美女xxoo啪啪120秒动态图 | 成人性生交大片免费视频hd| 亚洲美女视频黄频| 国产精品不卡视频一区二区 | 亚洲真实伦在线观看| 日本一本二区三区精品| 在线观看美女被高潮喷水网站 | 午夜免费激情av| 久久国产乱子免费精品| 欧美潮喷喷水| 午夜老司机福利剧场| 亚洲美女黄片视频| 成人一区二区视频在线观看| 免费人成视频x8x8入口观看| 国产三级中文精品| 中文字幕人妻熟人妻熟丝袜美| 国产黄色小视频在线观看| 国产高潮美女av| 亚洲不卡免费看| 免费看美女性在线毛片视频| 免费在线观看影片大全网站| 在线播放国产精品三级| 深爱激情五月婷婷| 国内精品美女久久久久久| 亚洲国产精品久久男人天堂| 国产精品自产拍在线观看55亚洲| 亚洲一区二区三区色噜噜| 中文字幕免费在线视频6| 国产精品自产拍在线观看55亚洲| 午夜福利在线观看免费完整高清在 | 麻豆成人av在线观看| 国产成人欧美在线观看| 久久久久久国产a免费观看| 九九在线视频观看精品| 成熟少妇高潮喷水视频| 久久久久久大精品| 欧美日韩黄片免| 蜜桃久久精品国产亚洲av|